MannKind Corporation (MNKD) Could Sink 90%: Tourbillion – ValueWalk Premium
MannKind

MannKind Corporation (MNKD) Could Sink 90%: Tourbillion

Hedge fund Tourbillion Capital Partners doesn’t like health care stock MannKind Corporation (NASDAQ:MNKD) and is betting it could tumble by as much as 90 percent, CNBC’s Lawrence Delevingne is reporting.


MannKind's Afrezza will fail due to potential customer backlash
Tourbillion thinks MannKind Corporation (NASDAQ:MNKD)’s lead diabetes treatment product, Afrezza, which recently won FDA approval, will fail . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0